AbbVie All-Oral Hep C Therapy gets Rapid EU Review
Cinnamon Girl said
Jun 21, 2014
(Reuters) - European regulators have validated AbbVie's application for an experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus and the therapy is now under accelerated assessment.
The U.S. drugmaker said on Tuesday the move by the European Medicines Agency meant that, if approved, its regimen could be available in the European Union in the first quarter of 2015. U.S. regulators have also granted the product priority review.
AbbVie's regimen consists of protease inhibitor ABT-450, boosted by a widely used antiviral called ritonavir, combined with polymerase inhibitor dasabuvir, and NS5A inhibitor ombitasvir with or without the older antiviral drug ribavirin.
(Reuters) - European regulators have validated AbbVie's application for an experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus and the therapy is now under accelerated assessment.
The U.S. drugmaker said on Tuesday the move by the European Medicines Agency meant that, if approved, its regimen could be available in the European Union in the first quarter of 2015. U.S. regulators have also granted the product priority review.
AbbVie's regimen consists of protease inhibitor ABT-450, boosted by a widely used antiviral called ritonavir, combined with polymerase inhibitor dasabuvir, and NS5A inhibitor ombitasvir with or without the older antiviral drug ribavirin.
http://www.reuters.com/article/2014/06/17/us-abbvie-europe-hepatitis-idUSKBN0ES0GW20140617